DENGVAXIA

This brand name is authorized in Brazil, Croatia, Estonia, Ireland, Lithuania, Poland, Singapore.

Active ingredients

The drug DENGVAXIA contains a combination of these active pharmaceutical ingredients (APIs):

`1`	Chimeric yellow fever dengue virus serotype 1 (live, attenuated)*
	Read more about
`2`	Chimeric yellow fever dengue virus serotype 2 (live, attenuated)
	Read more about
`3`	Chimeric yellow fever dengue virus serotype 3 (live, attenuated
	Read more about
`4`	Chimeric yellow fever dengue virus serotype 4 (live, attenuated)
	Read more about

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07BX04		J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BX Other viral vaccines
Discover more medicines within J07BX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	576720030057817, 576720030057917, 576720030058017, 576720030058117, 576720030058217
EE	Ravimiamet	1786529, 1786530, 1786541
LT	Valstybinė vaistų kontrolės tarnyba	1086818, 1086819, 1086820, 1086821, 1086822
PL	Rejestru Produktów Leczniczych	100416157
SG	Health Sciences Authority	15096P, 15097P

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.